The JuxtaFlow RAD uses negative pressure technique to protect the kidneys from hypoxia-induced damage during acute conditions. Credit: Magic mine/Shutterstock.com.

Roivios has secured the US Food and Drug Administration’s (FDA) breakthrough device designation for its JuxtaFlow renal assist device (RAD), designed to provide kidney protection for patients undergoing cardiac surgeries.

This designation follows the positive outcomes of the BIPASS-AKI feasibility study and aligns with new research presented at the Society of Cardiovascular Anesthesiologists (SCA) Annual Meeting.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The FDA’s breakthrough device designation recognises the JuxtaFlow RAD’s potential to transform the current treatment landscape for patients at risk of kidney disease.

This device employs a new negative pressure technique to protect the kidneys from hypoxia-induced damage during acute conditions.

At the SCA Annual Meeting, Roivios will present preclinical data that demonstrates the JuxtaFlow RAD’s efficacy in reducing the adverse effects of cardiopulmonary bypass on kidney function.

See Also:

This innovation has the potential to shorten ICU stays, decrease the necessity for emergency dialysis, and offer significant cost savings for healthcare systems.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roivios CEO John Erbey said: “Securing the breakthrough device designation marks a crucial milestone for Roivios and underscores our dedication to advancing kidney health innovation. We eagerly anticipate sharing the BIPASS-AKI clinical data soon. 

“We are proud to lead with innovative solutions like the JuxtaFlow RAD, which not only supports our unique approach but also our commitment to improving outcomes across a wide spectrum of conditions.”

With plans for the US launch in late 2025, Roivios aims to broaden the use of the JuxtaFlow RAD beyond cardiothoracic surgery to transform kidney health management across intensive care units.

In December 2023, the final participant was enrolled in the BIPASS-AKI study for the JuxtaFlow RAD at the Institute of Cardiovascular Diseases in Sremska Kamenica, Serbia.